BANCO SANTANDER S.A. (SAN)
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
📉 **NEGATIVE** • Low confidence analysis (33%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical